Clinical trials: Recurrent Endometrial Cancer
Genital Neoplasms, Female
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies.
- Trial name
- NCT05051696
- Testing
- H101
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Liu Zi
Endometrial Carcinoma
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
This is a randomized, double-blinded, placebo-controlled Phase 3 clinical trial to compare the combination of lerociclib (administered at 150 mg twice a day (BID) with letrozole (administered at 2.5 mg once a day (QD) to that of…
- Trial name
- NCT05712941
- Testing
- Lerociclib, Letrozole 2.5mg
- Sponsor
- EQRx International, Inc.
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well brivanib alaninate works in treating patients with endometrial cancer that has come back (recurred) or is persistent.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma
- Trial name
- NCT00888173
- Testing
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Where
- 35 sites in United States
- Volunteers
- 45 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Adenocarcinoma, Endometrial Cancer
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior…
- Trial name
- QLPPEC/GOG-003 (NCT06917092)
- Testing
- QL1706 combined with chemotherapy ± Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Ovarian Carcinoma, Recurrent Endometrial Carcinoma
Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma
The folate receptor is overexpressed in many types of cancer, including ovarian and endometrial cancer, and the level of folate receptor expression increases with the stage of the disease.
- Trial name
- NCT01689714
- Testing
- Tc 99m EC20
- Volunteers
- 16 people
- Sponsor
- Endocyte
Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
This phase II trial studies how well dasatinib works in treating patients with ovarian, fallopian tube, endometrial, or peritoneal cancer that has come back or is persistent.
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02059265
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 227 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Atezolizumab Trial in Endometrial Cancer - AtTEnd
Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1.
- Trial name
- AtTEnd (NCT03603184)
- Testing
- Atezolizumab, Paclitaxel, Carboplatin
- Where
- 93 sites in Australia, Austria and 9 more
- Volunteers
- 549 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Solid Tumors, Ovarian Cancer
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors
- Conditions
- Solid Tumors, Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT02476955
- Testing
- ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Endometrial Cancer, Gastrointestinal Complications
Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Post-operative radiotherapy is internationally accepted as standard practice in the management of high-risk endometrial cancer1. Whilst it has no proven impact on overall survival it significantly increases local control.
- Conditions
- Endometrial Cancer, Gastrointestinal Complications, Radiation Toxicity, Urinary Complications
- Trial name
- NCT01164150
- Testing
- 45 Gy/25 fractions
- Where
- 5 sites in Ireland
- Volunteers
- 92 people
- Sponsor
- Cancer Trials Ireland
Endometrial Cancer
AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)
This is an open-label nonrandomized multi-center study designed to evaluate the effect of AP23573 in patients with recurrent or persistent endometrial cancer.
- Trial name
- NCT00122343
- Testing
- ridaforolimus
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced Pelvic Cancer That Require Pelvic Exenteration
Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers
The Radium Hospital Oslo University Hospital Estimated date of first patient enrolled: 3rd quarter 2021 Anticipated recruitment period: 4 years Estimated date of last patient completed: 4th quarter 2025 Locally advanced pelvic…
- Trial name
- NCT05186493
- Testing
- robot-assisted total pelvic exenteration
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Endometrial Carcinoma
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer.
- Trial name
- NCT01455493
- Testing
- GDC-0980
- Where
- 28 sites in United States
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.